Revolution Medicines received Breakthrough Therapy Designation and entered into a major funding agreement, while activating international clinical trials in Europe and Japan.
4 reports, 1 independent
Updated Aug 8
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Revolution Medicines received Breakthrough Therapy Designation and entered into a major funding agreement, while activating international clinical trials in Europe and Japan.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Revolution Medicines (United States)
company in Redwood City, United States
Nothing else this week.
- FDA
-
Royalty Pharma
biopharmaceutical company based in New York City
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- FDA approval expands patient access to therapies for ACCORD.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Generic medicine services are seeking approval for launch from the FDA.
Coverage
Newest first; wire copies grouped- GlobeNewswireRevolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is windin
- Unknown outlet